Danish Medicines Council rejects Novartis breast cancer drug

During its May meeting, the Danish Medicines Councils has rejected breast cancer drug Piqray, which is developed by Novartis, and has partly reversed a prior rejection of acute myeloid leukemia (AML) treatment Xospata, developed by Astellas Pharma.
by albert rønning anderssen, translated by daniel pedersen

Yesterday, Novartis suffered a blow in Denmark.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading